CLASS II Drug recall · Reported 27 Jul 2022 · FDA Enforcement Report

Difluprednate Ophthalmic Emulsion recalled by CIPLA

CIPLA is recalling Difluprednate Ophthalmic Emulsion, 05%, distributed nationwide in the US. The recall was initiated on 14 Jul 2022 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesBatch# DEG4LC2, exp. date 05/2023
NDC69097-341
Quantity recalled8,136 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-1283-2022
FDA event ID
90608
Recalling firm
CIPLA, Warren, NJ
Manufacturer
Cipla USA Inc.
Classification
Class II
Status
Terminated
Recall initiated
14 Jul 2022
FDA classified
20 Jul 2022
Reported
27 Jul 2022
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Sterility
Drug class
Eye Drops

Timeline

14 Jul 2022Recall initiated by company
20 Jul 2022Classified by FDA+6 days
27 Jul 2022Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Lack of Assurance of Sterility: customer complaint for defective container where breakage of the protective cap exposes tip of eye drop which could compromise sterility.

A sterility recall means a product that must be sterile, such as an injection or eye drop, may be contaminated. Using a non-sterile product can cause serious infection.

Product as listed by the FDA

Difluprednate Ophthalmic Emulsion, 0.05%, 5ml bottles, Rx only, Mfd. by: Cipla Ltd., India At M/S Indoco Remedies Limited., L-32, 33, 34, Verna Industrial area, Verna - Goa, 403722, India; Mfd. for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, NDC 69097-341-35.

Where it was distributed

Nationwide in the USA

Nationwide

Questions about this recall

Is Difluprednate Ophthalmic Emulsion, 05% recalled?

Yes. CIPLA recalled Difluprednate Ophthalmic Emulsion, 05% on 14 Jul 2022. The recall is Class II and its status is Terminated. Recall number D-1283-2022.

Why was it recalled?

Lack of Assurance of Sterility: customer complaint for defective container where breakage of the protective cap exposes tip of eye drop which could compromise sterility.

Which lots are affected?

Batch# DEG4LC2, exp. date 05/2023

Where was it sold?

Nationwide in the USA

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from CIPLA

All 14
ReportedClassRecallCompanyReasonWhere
DrugCLASS IIPhytonadione Injectable Emulsion, USP 10mg/mL recalled by CiplaPhytonadioneCiplaPotency & AssayNationwide
DrugCLASS IIArformoterol Tartrate Inhalation Solution recalled by CIPLAArformoterol TartrateCIPLASterilityNationwide
DrugCLASS IIBudesonide Inhalation Suspension 25mg/, For Inhalation Only recalledBudesonideCIPLASterilityNationwide
DrugCLASS IIDifluprednate Ophthalmic Emulsion recalled by CIPLADifluprednateCIPLASterilityNationwide
DrugCLASS IIDifluprednate Ophthalmic Emulsion recalled by CIPLACIPLASterilityNationwide

Other Difluprednate recalls

All 3
ReportedClassRecallCompanyReasonWhere
DrugCLASS IIDifluprednate Ophthalmic Emulsion recalled by CIPLADifluprednateCIPLASterilityNationwide
DrugCLASS IIDifluprednate Ophthalmic Emulsion recalled by CIPLADifluprednateCIPLASterilityNationwide